ALTEROLA BIOTECH, INC. (OTCMKTS:ALTA) Files An 8-K Changes in Control of RegistrantITEM 5.01 – CHANGE IN CONTROL OF REGISTERANT.
On March 26th, 2018, Michael Frederick Freitag, the Company's President and CEO, and Krono Partners Limited completed a transaction with London Pharma Holdings Limited, which acquired 70,330,000 shares of common stock, representing 61.17% ownership of the Company. London Pharma Holdings Limited paid $200,000.00 in cash.
ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On March 26th, 2018, Mr. Freitag resigned from his official positions as Director and CEO of the Company, and on the same day the shareholders of the Corporation voted Mr. Peter Maddocks as Director, and CEO.
Peter Maddocks, 59, is a Chartered Accountant who brings decades of executive corporate financial experience to the Company. He has held positions at KPMG, was a senior financial controller with Citi Bank Private Banking in London, Citi Bank Italy and Citi Bank Venture Capital Emerging Markets Group. Mr. Maddocks is well versed in public company corporate affairs, holding Directorships in several publicly traded companies in the US as well as the UK.
ITEM 9.01 EXHIBITS
(d) Exhibits.
10.1Shareholder’s Resolution Appointing New Director
10.2Resignation of Michael Frederick Freitag
ALTEROLA BIOTECH INC. ExhibitEX-10.1 2 alterola_8ka-ex1001.htm RESOLUTION OF THE SHAREHOLDERS Exhibit 10.1 RESOLUTION OF THE SHAREHOLDERS OF ALTEROLA BIOTECH,…To view the full exhibit click here
About ALTEROLA BIOTECH, INC. (OTCMKTS:ALTA)
Alterola Biotech, Inc. is a development-stage company. The Company is focused on nutrition and health chewing gum with natural-based ingredients. It intends to expand its product line with gums having medical effects, such as painkillers and antihistamine medications with gum delivery. The Company’s products under development include Appetite suppressor, Cholesterol suppressor, Antioxidant gum, Motion sickness suppressor and Vitamin gum. Appetite suppressor is a chewing gum containing an extract of Hoodia gordonii and 2-hydroxyoleic acid, and is directed to treatment of obesity, hypertension and metabolic disorders. Cholesterol suppressor consists of Curcumin, the dietary polyphenol isolated from turmeric, which can inhibit cholesterol uptake in the enterocytes. It also focuses on pharmaceutical chewing gum, such as Painkiller and Anti-Histamine. As of March 31, 2016, the Company had not generated any revenues.
